

## **A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles**

*Huaqin Zuo, <sup>#\*a</sup> Junxian Tao, <sup>#b</sup> Manli Wang, <sup>c</sup> Xiaoyan Xie, <sup>a</sup> and Mei Sun <sup>\*a</sup>*

*a. Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University,  
Yangzhou, Jiangsu, 225001, P. R. China.*


*b. Department of Endocrinology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University,  
Yangzhou, Jiangsu, 225001, P. R. China.*

*c. Graduate School of Dalian Medical University, Dalian, Liaoning, 116044, P. R. China.*


# These authors contributed equally to this work.

\* Corresponding author.


E-mail address: [sybilzuo@163.com](mailto:sybilzuo@163.com) (H. Zuo); Mei Sun, [smzgwj@126.com](mailto:smzgwj@126.com) (M. Sun)




**Figure S1.** Fluorescence images of EL4 cells co-cultured with platelets for 24 hour. Rhodamine-labeled phalloidin was used to stain cytoskeletons (red) and DAPI stained nuclei (blue). FITC-labeled anti-CD41 antibodies were utilized to mark the platelet membranes. The conjugation of platelets and tumor cells was indicated by white arrows. Scale bar: 10  $\mu$ m.




**Figure S2.** P-Selectin expression levels in platelet membranes (PM) and PM-PLGA-DOX/GEM nanoparticles.




**Figure S3.** Positive area of CRT immunofluorescence on EL4 cells with different treatments. \*  $P < 0.05$ , \*\*  $P < 0.01$ .




**Figure S4.** Positive area of TUNEL staining in tumors isolated from mice that received different treatments. \*  $P < 0.05$ , \*\*  $P < 0.01$ .




**Figure S5.** Positive area of immunofluorescence for CRT (A), MDSCs (B) and CD8<sup>+</sup> T cells (C) in tumor tissues after different treatments. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .



**Figure S6.** MDSCs (CD11b<sup>+</sup>Gr-1<sup>+</sup>) in tumor tissues with different treatments quantified using flow cytometric analysis.



**Figure S7.** ELISA assay for TGF- $\beta$  (A) and IL-10 (B). Infiltrated MDSCs in tumors that received different treatments were isolated and cultured for 24 h. The supernatant was analyzed by ELISA assay. \* $P < 0.05$ , \*\* $P < 0.01$ .



**Figure S8.** Cytotoxic T lymphocytes (CTLs,  $CD3^+CD8^+$ ) in tumor tissues with different treatments quantified using flow cytometric analysis.